| [1] |
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities [J]. Clin J Am Soc Nephrol, 2017, 12(12): 2032-2045.
|
| [2] |
Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment [J]. Biomed Res Int, 2021, 2021(1): 1497449.
|
| [3] |
Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030 [J]. Kidney Int, 2023, 103(2): 282-296.
|
| [4] |
Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy [J]. J Am Soc Nephrol, 2008, 19(3): 433-442.
|
| [5] |
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets [J]. Nat Rev Immunol, 2011, 11(11): 723-737.
|
| [6] |
Dousdampanis P, Aggeletopoulou I, Mouzaki A. The role of M1/M2 macrophage polarization in the pathogenesis of obesity-related kidney disease and related pathologies [J]. Front Immunol, 2025, 15: 1534823.
|
| [7] |
Viola A, Munari F, Sánchez-Rodríguez R, et al. The metabolic signature of macrophage responses [J]. Front Immunol, 2019, 10: 1462.
|
| [8] |
Bellezza I, Giambanco I, Minelli A, et al. Nrf2-Keap1 signaling in oxidative and reductive stress [J]. Biochim Biophys Acta Mol Cell Res, 2018, 1865(5): 721-733.
|
| [9] |
Zhu Y, Sun L, Guo Z, et al. Curcumin/piperine modulates the butyrate levels and alleviates diabetic nephropathy via Nrf2/HO-1 signaling pathway [J]. Ren Fail, 2025, 47(1): 2538117.
|
| [10] |
Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease [J]. Nat Rev Dis Primers, 2015, 1: 15018.
|
| [11] |
Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy [J]. Int J Mol Sci, 2020, 21(8): 2806.
|
| [12] |
Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines [J]. Diabetes Obes Metab, 2020, 22(Suppl 1): 3-15.
|
| [13] |
Ricciardi CA, Gnudi L. Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies [J]. Metabolism, 2021, 124: 154890.
|
| [14] |
Youssef N, Noureldein MH, Riachi ME, et al. Macrophage polarization and signaling in diabetic kidney disease: a catalyst for disease progression [J]. Am J Physiol Renal Physiol, 2024, 326(3): F301-F312.
|
| [15] |
Porta C, Riboldi E, Ippolito A, et al. Molecular and epigenetic basis of macrophage polarized activation [J]. Semin Immunol, 2015, 27(4): 237-248.
|
| [16] |
Farooqui Z, Moreno JA, Rubio-Navarro A. Editorial: NRF2 signaling pathway: new insights in the field of reno-cardiovascular health [J]. Front Pharmacol, 2023, 14: 1193005.
|
| [17] |
Li R, Yan X, Zhao Y, et al. Oxidative stress induced by nuclear factor erythroid 2-related factor 2 (NRF2) dysfunction aggravates chronic inflammation through the NAD＋/SIRT3 axis and promotes renal injury in diabetes [J]. Antioxidants (Basel), 2025, 14(3): 267.
|
| [18] |
Ding L, Yuan X, Yan J, et al. Nrf2 exerts mixed inflammation and glucose metabolism regulatory effects on murine RAW264.7 macrophages [J]. Inte Immunopharmacol, 2019, 71: 198-204.
|
| [19] |
Zoccarato A, Smyrnias I, Reumiller CM, et al. NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway [J]. Cardiovasc Res, 2025，121(2): 339-352.
|
| [20] |
Tanase DM, Gosav EM, Anton MI, et al. Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease (DKD): new perspectives [J]. Biomolecules, 2022, 12(9): 1227.
|
| [21] |
Mi Y, Ahn TJ, Yu SM, et al. Nrf2 signaling pathway as a key to treatment for diabetic dyslipidemia and atherosclerosis [J]. Int J Mol Sci, 2024, 25(11): 5831.
|
| [22] |
Lin DW, Hsu YC, Chang CC, et al. Insights into the molecular mechanisms of NRF2 in kidney injury and diseases [J]. Int J Mol Sci, 2023, 24(7): 6053.
|
| [23] |
He F, Antonucci L, Karin M. NRF2 as a regulator of cell metabolism and inflammation in cancer [J]. Carcinogenesis, 2020, 41(4): 405-416.
|
| [24] |
Dodson M, Shakya A, Anandhan A, et al. NRF2 and diabetes: the good, the bad, and the complex [J]. Diabetes, 2022, 71(12): 2463-2476.
|
| [25] |
Wang L, He C. Nrf2-mediated anti-inflammatory polarization of macrophages as therapeutic targets for osteoarthritis [J]. Front Immunol, 2022, 13: 967193.
|
| [26] |
Zhao L, Tang S, Chen F, et al. Regulation of macrophage polarization by targeted metabolic reprogramming for the treatment of lupus nephritis [J]. Int Immunopharmacol, 2024, 128: 111476.
|
| [27] |
Mouton AJ, Li X, Hall ME, et al. Obesity, hypertension, and cardiac dysfunction: Novel roles of immunometabolism in macrophage activation and inflammation [J]. Circ Res, 2020, 126(6): 780-799.
|
| [28] |
de Haan JB. Nrf2 activators as attractive therapeutics for diabetic nephropathy [J]. Diabetes, 2011, 60(11): 2683-2684.
|
| [29] |
Ryan DG. Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response [J]. iScience, 2022, 25(2): 103827.
|
| [30] |
Ludtmann MHR, Angelova PR, Zhang Y, et al. Nrf2 affects the efficiency of mitochondrial fatty acid oxidation [J]. Biochem J, 2014, 457(3): 415-424.
|
| [31] |
Yan J, Horng T. Lipid metabolism in regulation of macrophage functions [J]. Trends Cell Biol, 2020, 30(12): 979-989.
|
| [32] |
Liu Y, Uruno A, Saito R, et al. Nrf2 deficiency deteriorates diabetic nephropathy in Akita model mice [J]. Redox Biol, 2022, 58: 102525.
|
| [33] |
Cruzat V, Macedo Rogero M, Noel Keane K, et al. Glutamine: metabolism and immune function, supplementation and clinical translation [J]. Nutrients, 2018, 10(11): 1564.
|
| [34] |
Yoo HC, Yu YC, Sung Y, et al. Glutamine reliance in cell metabolism [J]. Exp Mol Med, 2020, 52(9): 1496-1516.
|
| [35] |
Liu PS, Chen YT, Li X, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions [J]. Nat Immunol, 2023, 24(3): 452-462.
|
| [36] |
Zhou W, Hu G, He J, et al. SENP1-Sirt3 signaling promotes α-ketoglutarate production during M2 macrophage polarization [J]. Cell Rep, 2022, 39(2): 110660.
|
| [37] |
Feng R, Morine Y, Ikemoto T, et al. Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction [J]. Cell Commun Signal, 2018, 16(1): 54.
|
| [38] |
Han H, Gao Y, Chen B, et al. Nrf2 inhibits M1 macrophage polarization to ameliorate renal ischemia-reperfusion injury through antagonizing NF-κB signaling [J]. Int Immunopharmacol, 2024, 143 (Pt 1): 113310.
|
| [39] |
Sha W, Zhao B, Wei H, et al. Astragalus polysaccharide ameliorates vascular endothelial dysfunction by stimulating macrophage M2 polarization via potentiating Nrf2/HO-1 signaling pathway [J]. Phytomedicine, 2023, 112: 154667.
|
| [40] |
Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 [J]. Nature, 2018, 556(7699): 113-117.
|
| [41] |
Shao BY, Zhang SF, Li HD, et al. Epigenetics and inflammation in diabetic nephropathy [J]. Front Physiol, 2021, 12: 649587.
|
| [42] |
Bülow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold [J]. J Histochem Cytochem, 2019, 67(9): 643-661.
|
| [43] |
Wang X, Chen J, Xu J, et al. The role of macrophages in kidney fibrosis [J]. Front Physiol, 2021, 12: 705838.
|
| [44] |
Luo L, Wang S, Hu Y, et al. Precisely regulating M2 subtype macrophages for renal fibrosis resolution [J]. ACS Nano, 2023, 17(22): 22508-22526.
|
| [45] |
Feng Y, Ren J, Gui Y, et al. Wnt/β-catenin-promoted macrophage alternative activation contributes to kidney fibrosis [J]. J Am Soc Nephrol, 2018, 29(1): 182-193.
|
| [46] |
Wen J, Jiao B, Tran M, et al. Pharmacological inhibition of S100A4 attenuates fibroblast activation and renal fibrosis [J]. Cells, 2022, 11(17): 2762.
|
| [47] |
Klessens CQF, Zandbergen M, Wolterbeek R, et al. Macrophages in diabetic nephropathy in patients with type 2 diabetes [J]. Nephrol Dial Transplant, 2017, 32(8): 1322-1329.
|
| [48] |
Yang H, Xu W, Zhou Z, et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies [J]. Exp Clin Endocrinol Diabetes, 2015, 123(6): 360-367.
|
| [49] |
Manai F, Amadio M. Dimethyl fumarate triggers the antioxidant defense system in human retinal endothelial cells through Nrf2 activation [J]. Antioxidants (Basel), 2022, 11(10): 1924.
|
| [50] |
Li Z, Guo H, Li J, et al. Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function [J]. Clin Sci (Lond), 2020, 134(18): 2469-2487.
|
| [51] |
Zhang QY, Zhang HY, Feng SG, et al. Macrophage metabolic reprogramming ameliorates diabetes-induced microvascular dysfunction [J]. Redox Biol, 2025, 79: 103449.
|
| [52] |
Viola A, Munari F, Sánchez-Rodríguez R, et al. The metabolic signature of macrophage responses [J]. Front Immunol, 2019, 10: 1462.
|
| [53] |
Wang F, Zhang S, Vuckovic I, et al. Glycolytic stimulation is not a requirement for M2 macrophage differentiation [J]. Cell Metab, 2018, 28(3): 463-475.e4.
|
| [54] |
Gong N, Wang W, Fu Y, et al. The crucial role of metabolic reprogramming in driving macrophage conversion in kidney disease [J]. Cell Mol Biol Lett, 2025, 30(1): 72.
|
| [55] |
Li HD, You YK, Shao BY, et al. Roles and crosstalks of macrophages in diabetic nephropathy [J]. Front Immunol, 2022, 13: 1015142.
|
| [56] |
Wang M, Yao F, Chen N, et al. The advance of single cell transcriptome to study kidney immune cells in diabetic kidney disease [J]. BMC Nephrol, 2024, 25(1): 412.
|
| [57] |
Fu J, Sun Z, Wang X, et al. The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease [J]. Kidney Int, 2022, 102(6): 1291-1304.
|